Regulated expression of antigen and/or regulated attenuation to enhance vaccine immunogenicity and/or safety
US-10774334-B2 · Sep 15, 2020 · US
US11180765B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11180765-B2 |
| Application number | US-202016990033-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 11, 2020 |
| Priority date | May 10, 2007 |
| Publication date | Nov 23, 2021 |
| Grant date | Nov 23, 2021 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The invention relates to compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation and/or regulated expression of one or more antigens of interest.
Opening claim text (preview).
What is claimed is: 1. A recombinant bacterium capable of regulated expression of at least one nucleic acid sequence encoding a protein of interest, wherein the bacterium comprises: a. at least one chromosomally integrated nucleic acid sequence encoding a repressor operably linked to a regulatable promoter, wherein the nucleic acid sequence encoding the repressor and/or promoter have been modified from the wild-type nucleic acid sequence so as to optimize the expression level of the nucleic acid sequence encoding the repressor; b. a vector comprising at least one nucleic acid sequence encoding a protein of interest operably linked to a promoter regulated by the repressor, such that the expression of the nucleic acid sequence encoding the protein is repressed during in vitro growth of the bacterium, but the bacterium is capable of high level expression of the nucleic acid sequence encoding the protein in a host; and c. the mutation ΔrelA198::araC P BAD lacI TT. 2. The recombinant bacterium of claim 1 , wherein the bacterium further comprises a deletion in asd. 3. The recombinant bacterium of claim 1 , wherein the bacterium further comprises the mutation ΔasdA::TT araC PBAD c2. 4. The recombinant bacterium of claim 1 , wherein the repressor is selected from the group consisting of LacI, C2, and C1. 5. The recombinant bacterium of claim 1 , wherein the nucleic acid sequence encoding the repressor comprises a modified Shine-Dalgarno sequence and optimized codons so as to optimize the expression level of the nucleic acid sequence encoding the repressor. 6. The recombinant bacterium of claim 1 , wherein the vector is a plasmid. 7. The recombinant bacterium of claim 1 , wherein the nucleic acid encoding the protein of interest is operably linked to a Ptrc promoter. 8. The recombinant bacterium of claim 1 , wherein the protein of interest is toxic. 9. The recombinant bacterium of claim 1 , wherein the vector further comprises a nucleic acid sequence encoding a secretion signal for the protein of interest. 10. The recombinant bacterium of claim 1 , wherein the bacterium is capable of eliciting a protective immune response in the host. 11. The recombinant bacterium of claim 1 , wherein the bacterium comprises more than one means of attenuation. 12. The recombinant bacterium of claim 1 , wherein the repressor is LacI; the regulatable promoter is selected from the group consisting of P rhaBAD , P xyIAB , and P xyIFGH ; the vector is a plasmid; and the nucleic acid sequence encoding the protein of interest is operably linked to the Ptrc promoter. 13. The recombinant bacterium of claim 1 , further comprising a deletion in pabA and/or a deletion in pabB. 14. A composition comprising the recombinant bacterium of claim 1 . 15. A method for ameliorating one or more symptoms of a disease in a host, the method comprising administering to the host an effective amount of the composition of claim 13 . 16. A method for eliciting an immune response in a host, the method comprising administering to the host an effective amount of the composition of claim 13 .
Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) · CPC title
avirulent or attenuated · CPC title
Adaptation or attenuation of cells · CPC title
Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora · CPC title
expressing foreign proteins · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.